Cardiovascular Genetics Laboratory, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai 600036, Tamil Nadu, India.
Cardiovascular Genetics Laboratory, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai 600036, Tamil Nadu, India; Department of Biotechnology, Bennett University, Plot No. 8-11, Techzone II, Greater Noida 201310, Uttar Pradesh, India.
Drug Discov Today. 2022 Aug;27(8):2170-2180. doi: 10.1016/j.drudis.2022.05.003. Epub 2022 May 10.
Dysregulation of lipid metabolism is associated with cardiovascular/metabolic diseases, including atherosclerosis, liver diseases and type 2 diabetes mellitus (T2DM). Several miRNAs have been reported as regulators of different stages of lipid homeostasis, including cholesterol/fatty acid biosynthesis, degradation, transport, storage, and low-density (LDL) and high-density lipoprotein (HDL) formation. Indeed, various miRNAs are emerging as attractive therapeutic candidates for metabolic/cardiovascular disease (CVD). Here, we summarize the roles of miR-19b, miR-20a, miR-21, miR-27, miR-29, miR-34a, miR-144, miR-148a, and miR-199a in post-transcriptional regulation of genes involved in lipid homeostasis and their therapeutic potential. We also discuss experimental strategies for further development of these miRNAs as novel cardiometabolic therapeutics.
脂质代谢失调与心血管/代谢疾病有关，包括动脉粥样硬化、肝脏疾病和 2 型糖尿病（T2DM）。有几种 miRNA 被报道可调节脂质稳态的不同阶段，包括胆固醇/脂肪酸的生物合成、降解、运输、储存以及低密度脂蛋白（LDL）和高密度脂蛋白（HDL）的形成。事实上，各种 miRNA 作为治疗代谢/心血管疾病（CVD）的有吸引力的治疗候选物正在出现。在这里，我们总结了 miR-19b、miR-20a、miR-21、miR-27、miR-29、miR-34a、miR-144、miR-148a 和 miR-199a 在涉及脂质稳态的基因的转录后调节中的作用及其治疗潜力。我们还讨论了进一步开发这些 miRNA 作为新型心脏代谢治疗药物的实验策略。
